NEW YORK (GenomeWeb News) — Molecular diagnostic developer Immunexpress has garnered $6 million in financing led by Switzerland's Debiopharm Group, the companies said today.

Immunexpress, which has locations in Brisbane, Australia, and Seattle, said it will use the funding to advance development of its SeptiCyte technology and to bring one of its late-stage sepsis diagnostic products to market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.